IL-6R, Canine (HEK293, His)

IL-6R alpha is a subunit alpha of IL-6 receptors, also shared by other interleukin receptors. IL-6R alpha acts as IL-6 agonist and involves in JAK/STAT, MAPK, and Akt signaling pathway[1][2]. IL-6R alpha, Canine consists of 462 amino acids (M1-R462) and is produced in HEK293 cells with a C-Terminal His-tag.

LAPWGCPAPE VMSGVVTSLP GASVTLTCPG GEPEDNGTVQ WLLQNLVDDS YLGSRAAVGR TLLLRSVQLS DSGNYSCYQD GRLAGTVRLL VDAPPEEPQL ACFRKSPLSM VFCEWSPRHP PSPKTRATLL VRKFRGRPVG DSQEPCPYAQ GPQKFSCQLA VPEGDNSLYV VSLCVTNSAG SRSSTPQTFE GYGILQPDPP VNITVTAVDR NPRWLRVSWQ DPPSWNSYFY RLQFELRYRA ERSKTFTMLM IKEFQHHCII HDAWRGMRHV VQLRAREEFG HGSWSTWSQE AVGTPWTESR SPAAETELPH STQAPTTNED NKNNISKDIA NATSLPVQDS SSAPLP

[1]Garbers C, et al. Inhibition of classic signaling is a novel function of soluble glycoprotein 130 (sgp130), which is controlled by the ratio of interleukin 6 and soluble interleukin 6 receptor. J Biol Chem. 2011 Dec 16;286(50):42959-70.|[2]Malemud, et al. Defective JAK-STAT Pathway Signaling Contributes to Autoimmune Diseases. Curr Pharmacol Rep 4, 358-366.|[3]Larsen JV, et al. SorLA in Interleukin-6 Signaling and Turnover. Mol Cell Biol. 2017 May 16;37(11):e00641-16.|[4]Kang S, et al. Targeting Interleukin-6 Signaling in Clinic. Immunity. 2019 Apr 16;50(4):1007-1023.|[5]Giannitrapani L, et al. Circulating IL-6 and sIL-6R in patients with hepatocellular carcinoma. Ann N Y Acad Sci. 2002 Jun;963:46-52.|[6]Arnold P, et al. Joint Reconstituted Signaling of the IL-6 Receptor via Extracellular Vesicles. Cells. 2020 May 24;9(5):1307.|[7]Mishra AK, et al. Metformin inhibits IL-6 signaling by decreasing IL-6R expression on multiple myeloma cells. Leukemia. 2019 Nov;33(11):2695-2709.|[8]Gruber CN, et al. Mapping Systemic Inflammation and Antibody Responses in Multisystem Inflammatory Syndrome in Children (MIS-C). Cell. 2020 Nov 12;183(4):982-995.e14.